Drug intelligence / Profile preview

TOVAx

Development stage: Preclinical
Lead developer: PAI Life Sciences
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular, Parenteral

Overview

**TOVAx** is a preclinical recombinant protein vaccine program from PAI Life Sciences for prevention of onchocerciasis, also known as river blindness, caused by *Onchocerca volvulus*. The vaccine approach uses the parasite-derived recombinant antigens Ov-103 and Ov-RAL-2 to elicit protective antigen-specific immune responses, including antibody-mediated activity against infective larvae. PAI Life Sciences is developing the program with the Onchocerciasis Vaccine for Africa Initiative. ([pailifesciences.com](https://pailifesciences.com/pipeline/onchocerciasis/))

Targets

Ov-RAL-2 (Onchocerca volvulus retinol-binding protein-like 2)Ov-103 (Onchocerca volvulus Ov-103 antigen)

Beyond the preview

Go deeper on TOVAx.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TOVAx.

Explore the full profile